TGF-β/Smad Signaling


The TGF-β family is generally classified into two sub-families, TGF-β ligands, and bone morphogenic protein (BMP) ligands. In canonical signaling, receptor activation lead to phosphorylation of a group of transcription factors called Smads. TGF-β ligands bind to type II receptors (TGF-β II) which recruit and phosphorylate type I receptor (TGF-β I) on serine/threonine residues. The TGF-β I then recruits and phosphorylates a receptor regulated Smad (R-Smad). The R-Smad binds to the common Smad (Co-Smad) and forms a heterodimeric complex. This complex then translocates into the cell nucleus where it binds with nuclear co-factors to regulate the transcription of various target genes. Dysregulation of TGF-β/Smad signaling pathway is associated with a number of pathological conditions including fibrosis, cancer, immunodeficiency, diabetes and cardiovascular diseases etc.
-
B9001 Dibutyryl-cAMP, sodium salt9 CitationSummary: cell-permeable cAMP analog -
A3008 Y-27632 dihydrochloride72 CitationTarget: ROCKSummary: ROCK inhibitor -
A8192 Staurosporine21 CitationSummary: serine/threonine protein kinases inhibitor -
B1293 Y-2763240 CitationTarget: ROCKSummary: ROCK inhibitor -
A1805 Imatinib Mesylate (STI571)2 CitationTarget: PDGFR|c-Kit|Bcr-AblSummary: Abl/c-kit/PDGFR inhibitor -
B6096 SIS3Summary: Smad3 inhibitor -
B7807 Netarsudil (AR-13324)Target: ROCKSummary: ROCK inhibitor -
C3243 SafingolSummary: PKC and sphingosine kinases inhibitor -
C3523 HispidinSummary: protein kinase Cβ inhibitor -
C3656 ALK5 Inhibitor II (hydrochloride)Summary: ALK5 inhibitor

